Pentastarch

Identification

Name
Pentastarch
Accession Number
DB09111
Type
Small Molecule
Groups
Approved, Investigational
Description

Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is a subgroup of hydroxyethyl starch, with five hydroxyethyl groups out of each 11 hydroxyls, giving it approximately 50% hydroxyethylation. This compares with tetrastarch at 40% and hetastarch at 70% hydroxyethylation, respectively. It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. It is considered a plasma expander because it remains primarily intravascular after infusion.

Synonyms
Not Available
External IDs
ASL 607
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PentaspanSolution10 gIntravenousBristol Myers Squibb1993-01-272013-11-08Canada
International/Other Brands
StarQuin (Biomed)
Categories
UNII
MOQ3RNM0SV
CAS number
9005-27-0
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

The primary intended use of pentastarch is as a substitute for older colloids such as albumin or hetastarch for use in plasma volume expansion.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Pentastarch is hydrolyzed by plasma amylase. This is more rapid and complete compared to hetastarch.

Route of elimination

As a result of its lower molecular weight and lesser degree of substitution, pentastarch is eliminated from the circulation at a faster rate than hetastarch. Ordinarily, only 10% of an intravenous dose remains after 24 hours, and levels are undetectable after 4 to 7 days. Up to 70% of a dose is excreted in the urine within 24 hours.

Half life

~2.5 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AcrivastinePentastarch may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Pentastarch which could result in a higher serum level.
AdefovirAdefovir may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Food Interactions
Not Available

References

General References
  1. Younes RN, Yin KC, Amino CJ, Itinoshe M, Rocha e Silva M, Birolini D: Use of pentastarch solution in the treatment of patients with hemorrhagic hypovolemia: randomized phase II study in the emergency room. World J Surg. 1998 Jan;22(1):2-5. [PubMed:9465753]
External Links
PubChem Substance
347910411
Drugs.com
Drugs.com Drug Page
Wikipedia
Pentastarch
FDA label
Download (28.9 KB)
MSDS
Download (220 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableAvascular Necrosis of Hip / Total Hip Replacement Arthroplasty1
Not AvailableCompletedTreatmentElective Cesarean Section1
Not AvailableUnknown StatusTreatmentCardiopulmonary Bypass / Surgery, Cardiac1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous10 g
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on September 17, 2015 15:45 / Updated on November 02, 2018 06:58